Premium
Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines
Author(s) -
Toulza Frédéric,
Eliaou JeanFrançois,
Pinet Valérie
Publication year - 2005
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.20705
Subject(s) - chemokine , matrigel , angiogenesis , cancer research , monocyte , neovascularization , cxc chemokine receptors , secretion , biology , immunology , immune system , chemokine receptor , endocrinology
Abstract Tumor cells are known to interact closely with nontumoral infiltrating cells in order to grow and proliferate. Monocyte‐derived cells constitute a major component of the tumoral infiltrate and a high level of these cells has been associated with increased tumor growth and poor prognosis in patients with breast cancer. For their growth and metastatic propagation, solid tumors are dependant on angiogenesis and accumulated evidences suggest that monocyte‐derived cells could also play an important role in this phenomenon. However, the precise nature of proangiogenic factors secreted by these cells in breast carcinomas, and their direct influence on vessel formation, has not been determined. In the present study, we show that soluble factors secreted by breast tumor cells induce monocytes to produce a variety of proangiogenic CXC chemokines without secretion of angiostatic CXC chemokines. Using in vitro tubule formation in Matrigel, we demonstrated that the CXC chemokines secreted by MTSs (monocytes cultured with tumor cell supernatants) were able to induce microvessel formation. The profile of secreted CXC chemokines was characteristic for each tumor cell line or fresh tumor cells. This last result points out that a precise profiling of secreted proangiogenic factors inside the tumor, by tumor cells themselves or tumor‐infiltrating monocyte‐derived cells, is important for a precise targeting of therapeutic agents against neovascularization. © 2005 Wiley‐Liss, Inc.